Amarin Corp
NASDAQ: AMRN
$0.61
+$0.01 (+2.1%)
Closing Price on October 4, 2024
AMRN Articles
Jon OggThis week should be the end of the major earnings flood. With markets so close to highs, investors and traders alike are considering which stocks to buy and which ones to sell. 24/7 Wall St....
Published:
ThinkstockBiotech is a sector where investors know they are entering a high-stakes game of big risk and big reward. That is particularly the case for the small-cap biotech stocks that have no...
Published:
Jon OggEarnings season has started as Washington, D.C., seems to have figured a way out of its shenanigans again. Now investors really have to be wondering which stocks to buy and which to sell. 24/7...
Published:
via Wikimedia CommonsIt looks like Congress and the president still cannot figure out how to play well with each other, and now we have another impending government shutdown. The reality is that some...
Published:
ThinkstockThe world of biotech investing is always a difficult one. Often a binary event, such as a Food and Drug Administration (FDA) approval or a life-saving capital raise, is the difference...
Published:
Last Updated:
It may seem hard to believe, but some stocks are expected to rise by 50%, 100%, or even more over the next year. Our own DJIA peak price target is up 11.3% at 14,590, and that is a far cry from gains...
Published:
Last Updated:
U.S. equity markets opened higher this morning following a poor growth forecast from Europe and a better-than-expected report on U.S. unemployment. The German central bank said this morning that...
Published:
Last Updated:
ThinkstockBiopharmaceutical company Amarin Corp. PLC (NASDAQ: AMRN) announced after markets closed last night that it has received $100 million in nonequity financing from an investment fund managed...
Published:
Last Updated:
Jon OggThese are some of the top analyst upgrades, downgrades and initiations seen in Wall St. research calls this Tuesday. Amarin Corp. (NASDAQ: AMRN) started as Buy with $20 target at Citigroup....
Published:
Last Updated:
ThinkstockWe are tracking many key movers in the after-hours trading this Thursday. Most are earnings but some are not. Allscripts Healthcare Solutions Inc. (NASDAQ: MDRX) is up over 7% at $13.20 on...
Published:
Last Updated:
Amarin Corporation plc (NASDAQ: AMRN) is not exactly having a good day considering that its fish oil based drug for lowering triglycerides is not going to be a known event as soon as the company...
Published:
Last Updated:
Usually, shares of drug makers soar following the announcement that the Foood and Drug Administration approved a drug. Amarin Corp. (NASDAQ: AMRN) announced approval by the FDA for Vascepta to...
Published:
What usually happens when you get two mergers announced in drugs and biotech in the same day? Investors begin to wonder which other peers and competitors might be on the M&A block. Monday’s...
Published:
Last Updated:
More biotech mergers are on the way! That is the verdict of Wall St. There may be patent protection risks associated with future regulation under health care, but deals in the biotech and emerging...
Published:
Last Updated:
The freshly announced multibillion biotech buyout of Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) for more than $5 billion in equity value may be a bit misleading if you consider that it is...
Published:
Last Updated: